Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | STAT6 | P42226 | 8/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | INPPL1 | O15357 | 2/20 | 0.40 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13151570 | 0.85 | BLM (0.50) | BLMSRCSTAT6CA1CA2 | |
| SCHEMBL557322 | 0.81 | CA1 (0.49) | BLMNR4A1NR4A2NR4A3STAT6 | |
| SCHEMBL557324 | 0.81 | CA1 (0.49) | BLMNR4A1NR4A2NR4A3STAT6 | |
| SCHEMBL557323 | 0.81 | CA1 (0.49) | BLMNR4A1NR4A2NR4A3STAT6 | |
| SCHEMBL6655419 | 0.79 | CA1 (0.59) | NR4A1NR4A2NR4A3CA1CA2 | |
| SCHEMBL6655424 | 0.79 | CA1 (0.59) | NR4A1NR4A2NR4A3CA1CA2 | |
| SCHEMBL6655426 | 0.79 | CA1 (0.59) | NR4A1NR4A2NR4A3CA1CA2 | |
| SCHEMBL8058811 | 0.78 | BLM (0.61) | BLMSRCCA1CA2INPPL1 | |
| SCHEMBL16070000 | 0.78 | NR4A1 (0.51) | NR4A1NR4A2NR4A3CA1CA2 | |
| SCHEMBL16069999 | 0.78 | NR4A1 (0.51) | NR4A1NR4A2NR4A3CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841257-B2 | Inhibitors of STAT3 and uses thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-02-09 | — | — | US | disclosed |
| WO-2010118309-A2 | INHIBITORS OF STAT3 AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | STAT3, JAK2, STAT6 | BLM 3718/4885NR4A1 1016/4885NR4A2 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.